



RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

PATENT APPLICATION

1702.401900

#8  
H  
3-7-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
ROLF BJERKVIG ) : Examiner: J. Angell  
Appln. No.: 09/763,682 ) : Group Art Unit: 1633  
Filed: February 26, 2001 ) :  
For: ALGINATE CAPSULES FOR USE ) March 4, 2002  
IN THE TREATMENT OF ) :  
BRAIN TUMOR (As Amended) )

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT


Sir:

In the Office Action mailed December 4, 2001, the Examiner restricted the claimed invention into two groups: Group I, Claims 12, 13, 17 and 22; and Group II, Claims 12 and 23. The Examiner considered Claims 14-16, 18-21 and 24-28 to be generic to Groups I and II. In addition, the Examiner restricted the claims in each group into a set of species.

Applicant elects to proceed with the examination of the claims of Group I. Within Group I, Applicant elects claims specific for the species of "a molecule that is capable of affecting tumor neovascularization" if no generic claim is finally held to be allowable. The claims readable on the elected species are Claims 12, 13, 17, and 22.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

  
Attorney for Applicant  
John W. Behringer  
Registration No. 23,086

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200